Can L’Oréal-backed funding help OliX Pharmaceuticals turn siRNA science into a broader biotech platform?
Find out how OliX Pharmaceuticals’ KRW 110 billion raise could reshape RNAi therapeutics, beauty biotech, and siRNA platform strategy.
Can Mabwell’s anti-IL-11 antibody redefine scarring treatment through fibrosis reversal?
Mabwell doses first patient in Phase II trial of IL-11 antibody for pathological scarring. Find out what this means for fibrosis drug development.